Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease. (January 2016)

• Record Type: Journal Article
• Authors: Sinning, Christoph; Schnabel, Renate B; Zeller, Tanja; Seiffert, Moritz; Rupprecht, Hans J; Lackner, Karl J; Blankenberg, Stefan; Bickel, Christoph; Westermann, Dirk
• Is Part Of: Biomarkers in medicine. Volume 10:Number 1(2016)
• Page Start: 95
• Page End: 106
• Publication Date: 2016-01
• Subjects: angiogenesis -- coronary artery disease -- placental growth factor -- soluble fms-like tyrosine kinase-1 -- vascular endothelial growth factor; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/bmm.15.111
• Languages: English
• ISSNs: 1752-0363

Abstract

Background: Intention of the study is to assess the cardiovascular mortality of patients with coronary artery disease (CAD) with the biomarkers of angiogenesis PlGF and its endogenous inhibitor sFlt-1.Methods: The cohort included n = 1848 patients with CAD and 282 subjects without CAD. In 85 patients cardiovascular mortality, as combination of fatal myocardial infarction or any cardiac death, during a median follow-up duration of 3.9 years was reported.Results: In Kaplan–Meier curve analysis PlGF in rising thirds was not predictive regarding outcome (p = 0.54), the same was shown for sFlt-1 (p = 0.44). Cox regression for the fully adjusted model provided a hazard ratio (HR) of 0.8 (p = 0.18) for PlGF and for sFlt-1 a HR = 1.0 (p = 0.8).Conclusion: Our results point out that these biomarkers reflecting angiogenesis might not be suited to establish prognosis in CAD.